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ABSTRACT  19 
Introduction: The HIV-infected population is aging. Therefore, considerations concerning the 20 
effect of aging on the safety and efficacy of antiretroviral (ARV) therapy are needed. Nucleoside 21 
reverse transcriptase inhibitors’ (NRTIs) level of inhibition of viral reverse transcriptase is 22 
influenced by the ratio of intracellular metabolites (IM) to endogenous deoxynucleotides (EN) 23 
within the cell. We sought to examine the effect of aging on NRTI pharmacology in HIV+ men 24 
within the Multicenter AIDS Cohort Study (MACS).  25 
Methods: Stored peripheral blood mononuclear cell (PBMC) samples were analyzed from 152 26 
men (83 aged ≤45 years and 69 aged ≥60 years) enrolled in the MACS, receiving tenofovir 27 
disoproxil fumarate (TDF) and emtricitabine (FTC) with undetectable viral loads. Median values 28 
were based upon the Turnbull estimator, and a log-rank test was used to conduct the cross-29 
sectional analysis of IM:EN ratios between age groups. 30 
Results: The reported preliminary results suggest numerically increased median TFVdp and 31 
FTCtp concentrations within men aged ≥60 years. The TFVdp:dATP ratio was statistically 32 
significantly higher in men ≥60 years of age, compared to those ≤45 years of age (0.664 vs. 33 
0.294, P=0.0002). No statistically significant difference was found in the FTCtp:dCTP ratio 34 
between age groups.  35 
Conclusions: The elevated TFVdp:dATP ratio observed in men aged ≥60 years is likely a result 36 
of increased inflammation within the older population. The lack of a statistically significant 37 
difference in the FTCtp:dCTP ratio between groups may be explained by confounding increased 38 
cellular senescence within older men and/or the exclusion of ratios with measured dCTP below 39 
the limit of quantification.  40 
  41 
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INTRODUCTION 42 
As of 2015, the number of individuals within the United States living with diagnosed 43 
HIV infection was nearly 1 million. Among these individuals, the largest percentage was made 44 
up of those aged 50-54 years, and the greatest percentage increase in prevalence occurred in 45 
those greater than 65 years.(1) As the population infected with HIV continues to age, 46 
considerations must be made regarding the effect of aging on the safety and efficacy of 47 
antiretroviral (ARV) therapy. Physiologic changes, as a result of aging, that affect the 48 
pharmacokinetics of ARV therapy include decreased total body water, decreased albumin, 49 
increased adiposity, and reduced hepatic and renal function, together influencing the distribution 50 
and clearance of medications.(2) With increasing age also comes an increasing burden of 51 
comorbidities, which have been shown to develop up to 10 years sooner in HIV+ individuals 52 
than in those without HIV.(3) Further, it has been suggested that the prevalence of frailty is 53 
higher in HIV+ men, with increasing age.(4) HIV infection and aging result in similar changes in 54 
the immune system, including increased resting activation of T cells and low naïve CD4 cell 55 
levels.(5) Together, this suggests that aging plays a major role in the pharmacology of ARV 56 
therapy, however little research into this relationship has been conducted.  57 
Nucleoside reverse transcriptase inhibitors (NRTIs), used in combination, are often 58 
deemed the “backbone” of ARV therapy for the treatment of HIV infection.(6) Upon entry into 59 
target cells, NRTIs undergo phosphorylation to the active di- or tri-phosphate form. These 60 
intracellular metabolites (IM) inhibit viral replication through competitive binding to the viral 61 
reverse transcriptase molecule. IM compete with the corresponding endogenous 62 
2’deoxynucleotides (EN) within the cell, terminating the growing DNA chain when 63 
incorporated. Two common NRTIs used together as part of ARV combination regimens are 64 
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tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Tenofovir is metabolized to 65 
tenofovir diphosphate (TFVdp), which competes with 2’deoxyadenosine triphosphate (dATP).(7) 66 
Emtricitabine is metabolized to emtricitabine triphosphate (FTCtp), and competes with 67 
2’deoxycytidine triphosphate (dCTP) in the target cells.(8, 9)  68 
Given that IM compete with EN for binding of the viral reverse transcriptase molecule, 69 
the IM:EN ratio influences the level inhibition of viral reverse transcriptase. When IM:EN ratios 70 
are too low within the target cell, the result is reduced efficacy.(10) Too high an IM:EN ratio 71 
increases the risk of toxicity in patients, due to a potential for inhibition of host-cell DNA 72 
synthesis. Older NRTIs including zalcitabine, didanosine, and stavudine are associated with 73 
mitochondrial toxicity as a result of high affinity for and competitive inhibition of mitochondrial 74 
DNA polymerase gamma.(11) Depletion of the EN pool with agents such as hydroxyurea as a 75 
method to increase NRTI efficacy by increasing the IM:EN ratio was demonstrated to result in 76 
dose-limiting toxicities, mainly pancreatitis.(12) 77 
Recent work has examined the relationship between age, inflammatory markers, and 78 
NRTI pharmacology in The Women’s Interagency HIV Study (WIHS).(13) In that analysis, 79 
interleukin-6 (IL-6) and soluble CD163 (sCD163) were included as they have been linked to an 80 
increased risk of mortality in HIV+ individuals.(14–17) The current study seeks to further 81 
expand upon this previous work by exploring the effect of aging on NRTI pharmacology in 82 
HIV+ men within the unique, all-male population of the Multicenter AIDS Cohort Study 83 
(MACS). The objectives of the study are to examine the relationship between age and 84 




MATERIALS AND METHODS  87 
Study Population: Men enrolled in the MACS with viral load measurements <50 88 
copies/mL, who were receiving TDF/FTC as part of their ARV regimen at the time the viral load 89 
was recorded and had available stored PBMC pellets (non-viable), were included in the study. 90 
Acceptable stored PBMCs were no older than 10 years, with preference given to those 91 
corresponding to the last 3 visits. The cross-sectional study was conducted using specimens from 92 
men aged ≤45 years or ≥60 years at the time of sample collection. Exclusion criteria included the 93 
following: aged 46 to 59 years; reported nonadherence (defined several ways based upon MACS 94 
variables on Drug Form 1: MDPRE reported as <75%, MPILI reported as yes, or if ≥2 doses 95 
missed in the last 5 days); concomitant treatment with a NRTI other than TDF/FTC; receiving 96 
TDF/FTC as part of a research study; and concomitant use of corticosteroids, 97 
immunosuppressants, or drugs that alter the EN pool (hydroxyurea, mycophenolate, 98 
hydrochlorothiazide, ribavirin, anti-metabolites) during the 30 days prior to sample collection. 99 
Due to the potential for drug degradation, stored PBMCs that were not frozen within 24 hours of 100 
collection were excluded. When samples from multiple visits were available for a given patient, 101 
those corresponding to the earliest visit were used if the individual was ≤45 years and 102 
corresponding to the latest visit if the individual was ≥60 years. 103 
Measurement of IM and EN in PBMCs: The quantification of TFVdp, FTCtp, dATP, and 104 
dCTP within peripheral blood mononuclear cells (PBMCs), at each timepoint, was conducted by 105 
the UNC Center for AIDS Research (CFAR) Clinical Pharmacology and Analytical Chemistry 106 
(CPAC) Core, using a validated assay.(18) First, a protein precipitation extraction was 107 
performed. The samples were then analyzed by LC-MS/MS using anion exchange 108 
chromatography, with isotopically labeled TFVdp, dATP, and dCTP as internal standards. The 109 
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lower limit of quantification was 0.2 ng/mL for all analytes; concentrations were normalized to 110 
the PBMC count in each sample and converted to molar units, allowing calculation of a sample-111 
specific limit of quantification when analyte concentrations were below the limits of 112 
quantification. 113 
Statistical Analysis: Sample size calculations were based on the distributions of 114 
TFVdp:dATP and FTCtp:dCTP reported in the study by Dumond et al. entitled, p16INK4a, a 115 
Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected 116 
Subjects.(19) A sample size of 140 men, with 70 men ≤45 years and 70 men ≥60 years, would be 117 
required to provide approximately 83% power for TFVdp:dATP and 90% power for 118 
FTCtp:dCTP to detect a geometric mean ratio of  ≥1.30 between the age groups. The POWER 119 
procedure in SAS 9.3 was used for power calculations. Median values corresponding to the 120 
measured dATP, dCTP, FTCtp, and TFVdp concentrations were determined utilizing the 121 
Turnbull estimation method. The cross-sectional analysis of IM:EN ratios between age groups 122 
was conducted using a log-rank test, in order to account for IM measurements below the limit of 123 
quantification. IM:EN ratios in which the EN assay was below the limit of quantification were 124 
excluded from the analysis. When the IM concentration was below the limit of quantification, the 125 
sample-specific lower limit of quantification was imputed.  Medians were based upon the 126 
Turnbull estimator, as suggested by Gillespie, et al.(20) Data was analyzed in SAS 9.4 (SAS 127 
Institute Inc., Cary, NC). 128 
Study Approval: Demographic data and specimens were obtained under the approved 129 
MACS concept R18028 and analyzed in accordance with the data use agreement between the 130 
MACS Data Coordinating Center at Johns Hopkins University Bloomberg School of Public 131 
Health and the investigators at the University of North Carolina at Chapel Hill. This study was 132 
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deemed exempt from human subjects research oversight by the UNC Biomedical Institutional 133 
Review Board.  134 
 135 
RESULTS 136 
Baseline Characteristics. Samples from 152 unique individuals were obtained for 137 
analysis, with 83 samples corresponding to men aged ≤45 years and 69 samples corresponding to 138 
men aged ≥60 years (Table 1). Forty-eight men had available PBMC pellets from multiple 139 
patient visits; however, only PBMC concentration observations from the earliest visit within the 140 
younger group (≤45 years) or latest visit within the older group (≥60 years) were utilized in the 141 
analysis. The median age was 36.8 years in the younger group and 64.2 years in the older group. 142 
The majority of participants in the older group were white (77%), whereas the younger group 143 
included an increased proportion of black (30%) and Hispanic (39%) individuals. Quantitatively, 144 
more men within the older group had hypertension (61% vs. 18%) and diabetes (19% vs. 4%). 145 
Additionally, the older group included a numerically smaller percentage of current smokers 146 
(14% vs. 33%). PBMC concentration observations corresponding to 5 patients (6.0%) in the 147 
younger group and 16 patients (23.2%) in the older group were excluded from the TFVdp:dATP 148 
analysis due to dATP concentrations below the limit of quantification. Additionally, PBMC 149 
concentration observations from 8 patients (9.6%) in the younger group and 16 patients (23.2%) 150 
in the older group were excluded from the FTCtp:dCTP analysis, given dCTP measurements 151 
below the limit of quantification. 152 
Cross-Sectional Analysis.  The measured concentrations of the endogenous nucleotides 153 
and the NRTI intracellular metabolites for each age group are displayed in Table 2. Preliminary 154 
results showed values for each component of the TFVdp:dATP and FTCtp:dCTP ratios that were 155 
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numerically higher within men ≥60 years of age. The median TFVdp concentration was 52.1 156 
fmol/106 cells within the younger group versus 104 fmol/106 cells in the older group. Similarly, 157 
the median FTCtp concentration was 4902 fmol/106 cells in men aged ≤45 years, compared to 158 
5789 fmol/106 cells in men aged ≥60 years. Differences in endogenous nucleotide concentrations 159 
were less pronounced. Table 3 shows the TFVdp:dATP and FTCtp:dCTP ratios between age 160 
groups. The TFVdp:dATP ratio was statistically significantly higher in men aged ≥60 years, 161 
compared to those aged ≤45 years (0.664 vs. 0.294, P=0.0002). However, there was no 162 
statistically significant difference in the FTCtp:dCTP ratio between age groups (23.862 in men 163 
≥60 years vs. 23.008 in men ≤45 years, P=0.5179). Distributions of the TFVdp:dATP and 164 
FTCtp:dCTP ratios are further displayed in Figure 1. 165 
 166 
DISCUSSION 167 
Previous work has examined the relationship between age and TDF and FTC 168 
pharmacology in the Women’s Interagency HIV Study (WIHS).(13) Compared to the WIHS 169 
cohort, observed baseline CD4+ T-cell counts, CD4+:CD8+ T-cell ratios, eGFR values, and 170 
APRI scores were similar within the MACS. Key differences between the cohorts, however, are 171 
seen in their racial makeup. The majority of men in both the younger and older groups within the 172 
MACS were white (37% and 77%, respectively). Conversely, within the WIHS cohort, the 173 
majority of women were black (85% of women ≤45 years of age; 55% of women ≥60 years of 174 
age). Additionally, while the percentage of younger individuals identified as current smokers was 175 
similar between cohorts (33% in the MACS vs. 30% in the WIHS), a greater proportion of older 176 
women in the WIHS cohort were reported as current smokers (37% in the WIHS vs. 14% in the 177 
MACS). 178 
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Within the WIHS cohort, HIV+ women ≥60 years of age were found to have increased 179 
TFVdp:dATP and FTCtp:dCTP ratios compared to those ≤45 years of age. Although statistical 180 
significance was not maintained within the multivariable regression model that adjusted for 181 
various demographic and clinical factors, the directionality of these results were further 182 
maintained.(13) Within the MACS cohort of HIV+ men, we similarly found that the 183 
TFVdp:dATP ratio was elevated in those men aged ≥60 years, compared to those aged ≤45 184 
years. Additionally, a similar trend was seen towards higher TFVdp and FTCtp concentrations 185 
within the older group. This may be a result of increased inflammation within the older 186 
population, which has been suggested to contribute to an upregulation of the kinases involved in 187 
NRTI metabolism.(21) In contrast to the results seen in the WHIS cohort, no statistically 188 
significant difference was found between the FTCtp:dCTP ratio corresponding to men ≤45 years 189 
of age and those ≥60 years of age.(13) The lack of an observed difference between age groups 190 
may, in part, be due to the confounding factor of increased cellular senescence within older men. 191 
The tumor suppressor gene, p16INK4a, has been used as a biomarker of T-cell senescence and 192 
aging in individuals with HIV.(22) Recent work by Dumond et al. demonstrated that higher 193 
p16INK4a expression was associated with lower intracellular exposures of dATP, dCTP, and 194 
FTCtp.(23) Expression of p16INK4a was also a significant covariate in the clearance of TFVdp 195 
and FTCtp from PBMCs.(19) Therefore, increased cellular senescence within the older group 196 
may have mitigated the expected effects of increased inflammation on FTCtp concentrations, 197 
subsequently decreasing the FTCtp:dCTP ratio. 198 
A limitation of the current analysis is that the sample size of older individuals was 199 
slightly lower than the planned sample size of 70 men, based upon power analysis. In addition, 200 
the number of measured EN concentrations below the limit of quantification was unexpectedly 201 
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high, with a greater proportion within the older group. Measured dATP concentrations were 202 
below the limit of quantification in 5 men aged ≤45 years (6%), in contrast to 16 men ≥60 years 203 
of age (23.2%). Similarly, measured dCTP concentrations fell below the limit of quantification in 204 
8 men ≤45 years of age (9.6%), compared to 16 men aged ≥60 years (23.2%). By excluding the 205 
IM:EN ratios that contained an EN concentration below the limit of quantification, the sample 206 
sizes of both the older group and younger group were further decreased. Given the 207 
disproportionately higher percentage of EN concentrations below the limit of quantification in 208 
the older group, it is thought that there may have been a potential systematic issue in how the 209 
PBMC pellets were collected or stored. Although excluding TFVdp:dATP ratios with a 210 
measured dATP below the limit of quantification limited the sample size of both age groups, 211 
there was no observed change in the statistical significance of our findings compared to our 212 
analysis including those values. Conversely, excluding from the analysis FTCtp:dCTP ratios 213 
with dCTP measurements below the limit of quantification resulted in the loss of a statistically 214 
significant difference between age groups. Therefore, more confidence is placed in our 215 
TFVdp:dATP ratio results, as they were not sensitive to data exclusion. 216 
Of note, the results within this manuscript are preliminary. Given the systematically high 217 
number of samples with dATP or dCTP concentrations below the limit of quantification, 218 
particularly within the population of men aged ≥60 years, we plan to request a second aliquot to 219 
repeat the quantification of TFVdp, FTCtp, dATP, and dCTP. Additionally, a challenge that 220 
arose related to the project was that we were unable to obtain samples from the MACS until 221 
October of 2019, as a result of delays with the Data Use Agreement. Therefore, results related to 222 
the quantification of the inflammation markers, IL-6 and sCD163, within the all-male cohort of 223 
the MACS are still in progress; existing inflammatory biomarker data in the MACS cohort is 224 
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also available and will be assessed. These results will be included in the final manuscript to be 225 
submitted for publication once available. Importantly, gaining further insight into the 226 
inflammatory status of these patients will provide greater insight into potential explanations for 227 
our observed IM:EN ratios. Additionally, they will allow for a more robust comparison of our 228 
results to those observed within the all-female cohort of the WIHS. It has been suggested that, 229 
following ARV initiation, women maintain higher levels of inflammatory biomarkers compared 230 
to men.(24) Interestingly, in the WIHS, younger women were not found to have substantially 231 
lower cytokine concentrations, in contrast to what was initially hypothesized. Further, TFVdp 232 
was found to be negatively associated with sCD163 and IL-6 concentrations in younger 233 
women.(13) Whether these results are replicated within the all-male cohort of the MACS is left 234 
to be determined. By furthering our knowledge of the effect of aging on NRTI pharmacology 235 
within HIV+ patients, we can gain insight into how ARV therapy may be adjusted with 236 
increasing age to ultimately increase efficacy and decrease toxicity. 237 
  238 
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Table 1. Patient demographics at time of sample collection. 330 
Characteristica 
Age Group 
£ 45 y 
(n=83) 
³ 60 y 
(n=69) 
Age 36.8 (31.5, 41.6) 64.2 (61.8, 66.5) 
CD4+ T-cell count/mm3 673 (528, 856) 631 (475, 766) 
CD4:CD8+ T-cell ratio 0.84 (0.59, 1.19) 0.80 (0.60, 1.04) 
eGFRb, mL/min/1.73 m2 98.4 (87.3, 109.7) 74.2 (63.1, 89.7) 
APRIc score 0.28 (0.22, 0.35) 0.33 (0.28, 0.46) 
Hypertension   
Yes 15 (18%) 42 (61%) 
No 63 (76%) 25 (36%) 
Insufficient data 5 (6%) 2 (3%) 
Diabetes   
Yes 3 (4%) 13 (19%) 
No 69 (83%) 53 (77%) 
Insufficient data 11 (13%) 3 (4%) 
Smoking status   
Current smoker 27 (33%) 10 (14%) 
Race   
White 31 (37%) 53 (77%) 
Black 25 (30%) 16 (23%) 
Other 27 (33%) 0 (0%) 
Ethnicity   
Hispanic 32 (39%) 4 (6%) 
a Data is presented as median (25th, 75th percentile) or number (percentage).  331 
b eGFR: estimated glomerular filtration rate, as calculated by the CKD-EPI equation.  332 
c APRI: AST-to-platelet ratio index. 333 
  334 
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£ 45 y (n=83) ³ 60 y (n=69) 
dATP 127 (88.7, 279) 132 (87.2, 221) 
dCTP 212 (106, 319) 235 (138, 342) 
FTCtp 4902 (2488, 7883) 5789 (3597, 9115) 
TFVdp 52.1 (22.2, 77.9) 104 (69.5, 161) 
Data is presented as median (25th, 75th percentile). 336 
  337 
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Table 3. IM:EN ratios by age group. 338 
IM:EN Ratioa Age Group P-value ≤ 45 y ≥ 60 y 
TFVdp:dATP ratio 0.294 (0.150, 0.631)b 0.664 (0.373, 1.148)c 0.0002 
FTCtp:dCTP ratio 23.008 (15.787, 32.911)d 23.862 (18.702, 46.270)c 0.5179 
a Data is presented as median (25th, 75th percentile). 339 
b Data is from 78 patients. 340 
c Data is from 53 patients. 341 
d Data is from 75 patients. 342 
  343 
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 344 
Figure 1. Distributions of IM:EN ratios by age group. Observed (non-censored) and left-345 
censored IM:EN ratios are displayed, corresponding to men ≤45 years and men ³60 years. Left-346 
censored values represent those ratios in which the measured TFVdp or FTCtp concentration was 347 






















<= 45 yr >= 60 yr
Age group
Left-censoredObservedType of censoring
Distribution of TFVdp:dATP in two age groups (no right-
censoring)
Created by: macs_aim1_con.sas run on 28FEB20 at 14:06













<= 45 yr >= 60 yr
Age group
Left-censoredObservedType of censoring
Distribution of FTCtp:dCTP in two age groups (no right-
censoring)
Created by: macs_aim1_con.sas run on 28FEB20 at 14:06
Distribution of FTCtp:dCTP by Age Group
 21 
ADDENDUM 349 
Acknowledgements. The authors wish to thank Dr. Angela Kashuba, who provided oversight of 350 
the drug concentration analysis within the UNC CFAR CPAC Laboratory. We wish to thank Dr. 351 
Craig Lee for his continued support and valuable feedback throughout the RASP program. We 352 
wish to thank Ms. Catalina Ramirez and Dr. Andrew Edmonds at the UNC WIHS for their 353 
assistance interfacing with the MACS. Data in this manuscript were collected by the Multicenter 354 
AIDS Cohort Study (MACS). MACS (Principal Investigators): Johns Hopkins University 355 
Bloomberg School of Public Health (Joseph Margolick, Todd Brown), U01-AI35042; 356 
Northwestern University (Steven Wolinsky), U01-AI35039; University of California, Los 357 
Angeles (Roger Detels, Otoniel Martinez-Maza, Otto Yang), U01-AI35040; University of 358 
Pittsburgh (Charles Rinaldo, Lawrence Kingsley, Jeremy Martinson), U01-AI35041; the Center 359 
for Analysis and Management of MACS, Johns Hopkins University Bloomberg School of Public 360 
Health (Lisa Jacobson, Gypsyamber D'Souza), UM1-AI35043. The MACS is funded primarily 361 
by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding 362 
from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the 363 
National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects 364 
was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National 365 
Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also 366 
supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing 367 
Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and 368 
NIH Roadmap for Medical Research. The contents of this publication are solely the 369 
responsibility of the authors and do not represent the official views of the National Institutes of 370 
 22 
Health (NIH), Johns Hopkins ICTR, or NCATS. The MACS website is located 371 
at http://aidscohortstudy.org/. 372 
Funding Support. The current study was supported by 1R21AG063660-01A1 to JB Dumond. 373 
Conflicts of Interest. The authors have no conflicts of interest to disclose. 374 
